Psoriatic Arthritis News

This RSS feed URL is deprecated


This RSS feed URL is deprecated, please update. New URLs can be found in the footers at https://news.google.com/news

Tumor Necrosis Factor Inhibitor Persistence in Patients with Psoriatic Arthritis - Rheumatology Advisor



Rheumatology Advisor
 
Tumor Necrosis Factor Inhibitor Persistence in Patients with Psoriatic Arthritis 
Rheumatology Advisor
Female patients with psoriatic arthritis (PsA) and metabolic syndrome-related comorbidities are more likely to have lower tumor necrosis factor-alpha inhibitor (TNFi) persistence, and switching to a second TNFi therapy can be a valid therapeutic ...

 


Subcutaneous Secukinumab Relieves Psoriatic Arthritis - Medscape



Medscape
 
Subcutaneous Secukinumab Relieves Psoriatic Arthritis 
Medscape
SAN DIEGO ? For patients with active psoriatic arthritis, the human interleukin (IL)-17A antagonist secukinumab (Cosentyx, Novartis Pharmaceuticals), administered by subcutaneous injection, significantly improved disease activity at 16 weeks ...

 


Draft Psoriatic Arthritis Guideline Presented at ACR 2017 - Rheumatology Advisor



Rheumatology Advisor
 
Draft Psoriatic Arthritis Guideline Presented at ACR 2017 
Rheumatology Advisor
SAN DIEGO ? The authors of the updated American College of Rheumatology (ACR)/National Psoriasis Foundation (NPF) guideline for psoriatic arthritis (PsA) presented their draft recommendations at the 2017 ACR/ARHP Annual Meeting. The guideline ...

 


Abatacept Improves Outcomes in Patients With Active Psoriatic Arthritis - Rheumatology Advisor



Rheumatology Advisor
 
Abatacept Improves Outcomes in Patients With Active Psoriatic Arthritis 
Rheumatology Advisor
SAN DIEGO ? Administration of abatacept may improve patient-reported outcomes (PROs) in individuals with active psoriatic arthritis and elevated levels of C-reactive protein (CRP), irrespective of tumor necrosis factor inhibitor (TNFi) treatment ...

 


Tofacitinib or Adalimumab vs Placebo for Patients With Psoriatic Arthritis - Rheumatology Advisor



Rheumatology Advisor
 
Tofacitinib or Adalimumab vs Placebo for Patients With Psoriatic Arthritis 
Rheumatology Advisor
Treatment with tofacitinib 5 or 10 mg demonstrated superior efficacy to placebo in several clinical domains of psoriatic arthritis at 3 months, according to the results of a 12-month, phase 3, randomized, placebo-controlled, double-blind trial ...

 


Therapeutic Goal Achievement Independent of Cardiovascular Risk in Psoriatic Arthritis - Rheumatology Advisor



Rheumatology Advisor
 
Therapeutic Goal Achievement Independent of Cardiovascular Risk in Psoriatic Arthritis 
Rheumatology Advisor
SAN DIEGO ? With the exception of sedentary lifestyle, cardiovascular risk factors were not found to have an impact on the likelihood of achieving minimal disease activity among patients with psoriatic arthritis, according to research to be presented ...
Psoriatic Arthritis Therapeutics Market Analysis and Value Forecast Snapshot by End-use Industry 2017-2025 LANews By Abhishek Budholiya (press release) (blog)

all 2 news articles » 


Higher Prevalence of Depression, ADHD Observed Among Women With Psoriatic Arthritis - Rheumatology Advisor



Rheumatology Advisor
 
Higher Prevalence of Depression, ADHD Observed Among Women With Psoriatic Arthritis 
Rheumatology Advisor
SAN DIEGO ? Researchers observed a higher prevalence of psychiatric disorders, including attention-deficit/hyperactivity disorder (ADHD) and depression, among female patients with psoriatic arthritis (PsA) compared with male patients, according to ...
Psoriatic Arthritis Symptoms Reduced In Novartis Cosentyx Study Pharmaceutical Processing

all 4 news articles » 


ACR and NPF Unveil New Clinical Guideline for Treating Psoriatic Arthritis - AJMC.com Managed Markets Network



ACR and NPF Unveil New Clinical Guideline for Treating Psoriatic Arthritis 
AJMC.com Managed Markets Network
On Tuesday afternoon, the American College of Rheumatology (ACR) and the National Psoriasis Foundation (NPF) presented a draft of their new, jointly developed clinical guideline for treating psoriatic arthritis (PsA), at the ACR 2017 Annual Meeting.
ACR/ARHP 2017: Long-Term Use of Lilly's Taltz® (ixekizumab) Shows Efficacy Improvements in Psoriatic Arthritis for ... Markets Insider
Eli Lilly & Co. (LLY) Says Long-Term Use of Taltz Shows Efficacy Improvements in PsA at ACR/ARHP StreetInsider.com

all 3 news articles » 


Tofacitinib Improves Patient-Reported Outcomes for Active Psoriatic Arthritis - Rheumatology Advisor



Rheumatology Advisor
 
Tofacitinib Improves Patient-Reported Outcomes for Active Psoriatic Arthritis 
Rheumatology Advisor
SAN DIEGO ? Tofacitinib significantly improved patient-reported outcomes among patients with active psoriatic arthritis, according to the results from phase 3 trials OPAL Broaden (12 months; ClinicalTrials.gov identifier: NCT01877668) and OPAL Beyond ...

 


Study Supports Use of Intravenous Golimumab in Treating Psoriatic Arthritis - AJMC.com Managed Markets Network



Study Supports Use of Intravenous Golimumab in Treating Psoriatic Arthritis 
AJMC.com Managed Markets Network
Recently reported results of a phase 3 study found that patients with psoriatic arthritis (PsA) who received intravenous golimumab (Simponi) had significantly greater improvements in the signs and symptoms of PsA through week 24 than did patients who ...